# Characterization of the Long-term Safety, Efficacy, and Pharmacodynamics Revestive® in the Management of Short Bowel Syndrome Pediatric Patients

> **NCT03562130** · PHASE4 · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 25 (actual)

## Conditions studied

- Short Bowel Syndrome

## Interventions

- **DRUG:** Teduglutide

## Key facts

- **NCT ID:** NCT03562130
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-02
- **Primary completion:** 2019-12-11
- **Final completion:** 2020-07-13
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2025-09-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03562130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03562130, "Characterization of the Long-term Safety, Efficacy, and Pharmacodynamics Revestive® in the Management of Short Bowel Syndrome Pediatric Patients". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03562130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*